 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Research > Epoch BioSciences, Inc.
 |
Epoch BioSciences, Inc. |
 |
 |
 |
PROFILE |
 |
Epoch BioSciences designs, synthesizes, and modifies oligonucleotides (synthetic strands of DNA) to facilitate the genetic analysis of humans, animals, and plants. Operating on the premise that hereditary diseases are produced by abnormal protein production in a person's DNA and RNA, the company is developing oligonucleotides to bind and interact with genetic material to detect and find the cause of cancer, heart disease, arthritis, and other chronic illnesses. Epoch BioSciences has a licensing agreement with Applied Biosystems Group and is incorporating its technology into Applied Biosystems' TaqMan assays. Illinois investment firm Grace Brothers owns about 20% of Epoch BioSciences.
COMPETITION |
 |
Clontech Laboratories, Inc. (dossier)
Orchid BioSciences, Inc. (ORCH)
Third Wave Technologies, Inc. (TWTI)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 1.40
1-Yr. Sales Growth: 600.0%
Employees: 51
Revenue per employee: $27,450.98
KEY PEOPLE |
 |
William G. Gerber
CEO
Bert W. Hogue
CFO
CONTACT INFO |
 |
21720 23rd Dr. SE, #150
Bothell, WA 98021
US
Phone: 425-482-5555
Fax: 425-482-5550
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |